Incremental cost-effectiveness ratios (in $US per quality-adjusted life-years) of different approaches to patients aged 20 to 64 years with influenza-like illness (ILI) from the societal perspective for pandemic influenza or high risk patients.
收藏NIAID Data Ecosystem2026-03-06 收录
数据链接：
官方服务：
资源简介：
Comparator: Do nothing. †(Sensitivity). *(Sensitivity/Specificity). Bold Text: Strategy is cost effective (ICER versus Do Nothing is <$50,000 per QALY). Bold and Italic Text: Strategy is economically dominant (costs less and is more effective than Do Nothing).
创建时间：
2010-06-23
